• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by InMed Pharmaceuticals Inc.

    12/18/24 8:05:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    InMed Pharmaceuticals Inc.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    457637601

    (CUSIP Number)


    12/13/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    YA II PN, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    YA Global Investments II (U.S.), LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    Yorkville Advisors Global, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    Yorkville Advisors Global II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    YA II GP, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    YAII GP II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    Mark Angelo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    457637601


    1Names of Reporting Persons

    SC-Sigma Global Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    80,372.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    80,372.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    80,372.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    InMed Pharmaceuticals Inc.
    (b)Address of issuer's principal executive offices:

    Suite 1445-855 W. Georgia Street Vancouver, A1, V6C 3E8
    Item 2. 
    (a)Name of person filing:

    YA II PN, Ltd.
    (b)Address or principal business office or, if none, residence:

    1012 Springfield Avenue, Mountainside, NJ 07092
    (c)Citizenship:

    Cayman Islalnds
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    457637601
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    80,372
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    80,372

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    80,372

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with InMed Pharmaceuticals Inc. (the "Issuer"), on December 13, 2024. Under the SEPA, the Issuer has the option to sell up to $10 million of its Common Shares to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of Common Shares beneficially owned by YA II and its affiliates to exceed 9.99% of the outstanding Common Shares of the Issuer. YA II is beneficially owned by YA Global Investments II (U.S.), LP (the "YA Feeder"). Yorkville Advisors Global, LP (the "YA Advisor") is the investment manager to YA II. Yorkville Advisors Global II, LLC (the "YA Advisor GP") is the general partner to the YA Advisor. YAII GP, LP (the "YA GP") is the general partner to the YA Feeder. YAII GP II, LLC (the "Yorkville GP") is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares. YAII GP, LP is the general partner of SC-Sigma Global Partners, LP ("SC-Sigma"), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares. For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    YA II PN, Ltd.
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
     
    YA Global Investments II (U.S.), LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
     
    Yorkville Advisors Global, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
     
    Yorkville Advisors Global II, LLC
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
     
    YA II GP, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
     
    YAII GP II, LLC
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
     
    Mark Angelo
     
    Signature:/s/ Mark Angelo
    Name/Title:Mark Angelo
    Date:12/18/2024
     
    SC-Sigma Global Partners, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/18/2024
    Get the next $INM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INM

    DatePrice TargetRatingAnalyst
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $INM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:54 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:35 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Klompas Neil A

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:16 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    11/29/21 6:20:24 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on InMed Pharmaceuticals with a new price target

    Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously

    2/16/21 11:09:34 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for December 11th

    NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please Schedule 1x1 Meetings Here "We are excited to host our Life Sciences Virtual Investor Forum on December 11th," said Jason Paltrowitz,

    12/9/25 8:35:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

    Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed's CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18th    TIME: 2:00 PM ET LINK:  REGISTER HEREAvailable for 1x1 meetings: Sept

    9/16/25 1:39:13 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    SEC Filings

    View All

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 8:51:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by InMed Pharmaceuticals Inc.

    10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 5:04:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by InMed Pharmaceuticals Inc.

    SCHEDULE 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    1/20/26 2:25:27 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/22/24 1:38:46 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/21/24 2:58:17 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Leadership Updates

    Live Leadership Updates

    View All

    InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

    VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid

    12/12/22 6:47:35 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Announces Changes to its Board of Directors

    VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets.  Throughout her career, Ms. Lemerond has worked with public

    8/9/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Announces Appointment of Chief Operating Officer

    VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa

    7/18/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Financials

    Live finance-specific insights

    View All

    InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

    VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w

    9/19/22 6:00:00 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

    Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,

    2/14/22 7:34:02 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

    VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available

    2/10/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

    SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/12/24 1:44:16 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc. (Amendment)

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    2/14/24 2:28:27 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care